Fundraising FoxFoster City · Series B–Late Stage · 17 people tracked
Find your way into Gilead Sciences
364 people in our graph share verified history with the Gilead Sciences team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Gilead's research and development approach centers on pursuing transformative medicines and cures across three therapeutic areas: virology, oncology and inflammation. Drawing on a 35-plus-year track record, the company identifies best-in-class molecules, biologics, cell therapies and combinations and advances them quickly. It has helped turn public health challenges such as HIV and hepatitis C into manageable or curable conditions, and is developing therapies across viral hepatitis, SARS-CoV-2 and potential pandemic viruses. In oncology it seeks treatments offering long-term remission and cures, while in immunology it targets next-generation therapies for inflammatory and fibrotic diseases. The company set an ambition in 2019 to deliver 10-plus transformative therapies by 2030.
Source: firm website, verified Aug 16, 2026.
Team · 17 people
from the firm's website
What they invest in
from 9 of 9 portfolio companiesBiotech ×9Healthtech ×5AI & Machine Learning ×2Medical Devices ×2Deep Tech ×1Digital Health ×1SaaS ×1
HQs:United States×6
Investments · 10 tracked
founders shown can be your intro pathBy year:2023 · 12022 · 12021 · 22018 · 26 dated
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Arie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDavid Chang, M.D., Ph.D.(Co-Founder, Allogene; former President and Chief Executive Officer)Christine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer; one of the founders of Allogene)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Co-Founder and Director of Allogene)
Co-investorsAvoro Capital AdvisorsForesite CapitalTPGVida VenturesVVAG Special
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesVida VenturesWestlake Village BioPartnersKleiner PerkinsOxford Finance LLCRTW Investments L.P.+1 more
Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.
AI & Machine LearningBiotechHealthtech
Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)inCourtney Beers(Chief Scientific Officer)
Co-investorsCanaan PartnersMPM BioImpactAbingworthAstellas Venture Management LLCLightstone Ventures
Curebase provides a software platform for clinical trial management, serving contract research coordinators and trial sites.
AI & Machine LearningBiotechDigital HealthHealthtechSaaSFort Lauderdale, US
Storm Stillman(Chief Executive Officer)inTom Lemberg(Founder)in
Co-investorsAcrew CapitalBold Capital PartnersBreyer CapitalFuture Planet CapitalNotable CapitalXfund+7 more
Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.
BiotechCambridge, US
Gabriel Kwong(Executive Officer)inSangeeta BhatiainRoopom Banerjee(Executive Officer)in
BoardTheresia Gouw(Director)inAmy Schulman(Director)Stan Lapidus(Director)in
Co-investorsGreatPoint VenturesAcrew CapitalARCH Venture PartnersAspect VenturesCatalio Capital ManagementCRV (Charles River Ventures)+6 more
Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.
BiotechDeep TechHealthtechMedical Devices
BoardSrini Akkaraju(Director, Founder)inPaul Kang(Director, Founder)
Co-investorsVersant VenturesSamsara BioCapital
Tmunity Therapeutics was a University of Pennsylvania spinout developing engineered T-cell therapies, including CAR-T and TCR-based treatments, for cancers.
BiotechPhiladelphia, US
Anne Chew(Director and President)
BoardKevin Mahoney(Director)
Co-investorsAndreessen HorowitzKhosla VenturesKleiner PerkinsLAVLilly Asia VenturesMilitia Hill Ventures
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies that direct T cells to address autoimmune and inflammatory diseases.
BiotechHealthtech
Co-investorsFuture Planet Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 3
2 IPOs · 1 acquisitions · showing 2Allogene TherapeuticsNASDAQ: ALLOKyverna TherapeuticsNASDAQ: KYTX
Portfolio news
latest coverage across their companiesCurebase · curebase.ai · May 6, 2025
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Allogene Therapeutics | 6.5% | $18.00 | Oct 2018 | $134.8M |
| Kyverna Therapeutics | 7.9% | $22.00 | Feb 2024 | $70.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Gilead Sciences made?
- Gilead Sciences has 9 tracked investments, 3 of which have exited.
- What stage does Gilead Sciences invest at?
- Gilead Sciences invests at the Series B, Series C, Late Stage stages.
- What sectors does Gilead Sciences focus on?
- Gilead Sciences focuses on Advanced Manufacturing, Biotech, Healthtech, SaaS.
- Where is Gilead Sciences located?
- Gilead Sciences is headquartered in Foster City, US.
Media · Podcasts & interviews
featuring the teamGilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
CNBC Television · Daniel O’Day
Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation.
PhRMA · Daniel O’Day
Watch CNBC's full interview with Gilead Sciences chairman and CEO Daniel O’Day
Daniel O’Day · cnbc.com
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blume Ventures is a seed and pre-Series A investment firm headquartered in Mumbai that focuses on early-stage companies in India.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
West Virginia Jobs Investment Trust is a publicly-funded venture capital provider that invests in eligible West Virginia businesses to support job creation and economic development within the state.